Chemo-immunotherapy before surgery for head and neck cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial tests combining immunotherapy (camrelizumab) with standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors more effectively and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell carcinoma in your mouth or voice box, stage III or IVA.
- Your doctor plans to remove the tumor with surgery.
- You are 18 to 75 years old.
- You have not had any previous treatment for this cancer.
- A tissue sample from your tumor is available for testing.
- You have no other active cancers (except very minor skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining an immunotherapy drug (camrelizumab) with another targeted therapy or chemotherapy given before and after surgery can improve outcomes for people with locally advanced head and neck cancer. It aims to see if this approach is more effective than standard treatments.
This trial tests two drugs—camrelizumab (an immunotherapy) and dalpiciclib (a targeted therapy)—given before surgery for head and neck squamous cell carcinoma that can be removed. The goal is to see if this combination helps shrink the tumor and improves outcomes.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests whether giving a combination of immunotherapy drugs (pembrolizumab, N-803, and possibly PD-L1 t-haNK cells) before surgery can help treat head and neck cancer that has not been treated yet. It is for people whose cancer is p16-negative (a specific marker) and is at an intermediate or high risk of coming back.
This trial tests a combination of penpulimab (an immunotherapy drug) and chemotherapy before and after surgery for head and neck cancer. The goal is to see if this approach can improve treatment outcomes for people with resectable (removable by surgery) cancers.
Hear when a new Squamous Cell Carcinoma of Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.